Detalles de la búsqueda
1.
Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
BMC Dermatol
; 18(1): 4, 2018 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29954363
2.
Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
J Drugs Dermatol
; 16(12): 1246-1252, 2017 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29240860
3.
Predictors of self-reported benign prostatic hyperplasia in European men: analysis of the European National Health and Wellness Survey.
World J Urol
; 33(5): 639-47, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25100623
4.
Osteoporosis and treatments in Japan: management for preventing subsequent fractures.
J Bone Miner Metab
; 31(4): 367-80, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23536192
5.
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
BMC Womens Health
; 13: 15, 2013 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-23521803
6.
Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
BMC Musculoskelet Disord
; 14: 4, 2013 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-23281846
7.
Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Curr Med Res Opin
; 38(5): 653-660, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34761723
8.
Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).
J Med Econ
; 25(1): 1030-1038, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35971655
9.
Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm.
Adv Ther
; 38(8): 4442-4460, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264500
10.
Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study.
Curr Med Res Opin
; 37(3): 443-457, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33331205
11.
A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe.
J Patient Rep Outcomes
; 4(1): 53, 2020 Jul 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32632891
12.
Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database.
Curr Med Res Opin
; 36(1): 51-61, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31422701
13.
Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database.
J Med Econ
; 23(11): 1356-1364, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32845189
14.
Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.
J Med Econ
; 22(9): 849-858, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30977712
15.
Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
J Manag Care Spec Pharm
; 25(1): 46-59, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30044691
16.
Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates.
BMC Womens Health
; 8: 24, 2008 Dec 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-19105828
17.
Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine.
Patient Prefer Adherence
; 12: 2413-2424, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30519007
18.
Direct and Indirect Costs Among United States Commercially Insured Employees With Migraine.
J Occup Environ Med
; 60(12): 1120-1127, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30199470
19.
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
J Med Econ
; 20(12): 1224-1230, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28760056
20.
Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis.
J Med Econ
; 20(9): 982-990, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28635342